How Can We Help You?

Category Archives: Substance Abuse and Mental Health Services Administration (SAMHSA)

happy people stacking hands outdoor

Bizzell Awarded Four SAMHSA IDIQ Domains

FOR IMMEDIATE RELEASE

The Bizzell Group Contact
Chad Brown DM, Chief Administrative Officer
301-459-0100 | cbrown@thebizzellgroup.com

The Bizzell Group (Bizzell), a global strategy, consulting, and technology firm, is excited to continue its successful partnership with the Substance Abuse and Mental Health Services Administration (SAMHSA). Bizzell has been awarded four domains as a prime contractor on SAMHSA’s Indefinite Delivery Indefinite Quantity (IDIQ) contract through 2027. The IDIQs help SAMHSA achieve its goal of reducing the impact of substance abuse and mental illness on America’s communities.

Through this award, Bizzell is eligible to compete for new contracts under the following domains:

  • Domain I: Feasibility, Pilot, and Evaluation Projects
  • Domain II: Statistical Projects
  • Domain V: Technical Assistance and Training Projects
  • Domain VI: Planning, Implementation, and Report Support Projects (8a and HUBZone)

Since Bizzell’s inception, the firm has worked with SAMHSA and other agencies within the Department of Health and Human Services to accelerate behavioral health advancements and improve services and resources for communities within the United States and across the globe. Bizzell has a full range of capabilities that can support SAMHSA’s mission, and includes program and project management, data analytics, evaluation and learning, and technical assistance and training.

Bizzell has conducted a wide range of feasibility studies, evaluation projects, and didactic learning seminars to strengthen health system interventions and training, foster data-informed decisions, and improve program outcomes and impact. Specifically, we’ve partnered with SAMHSA to provide direct technical assistance and support services to opioid treatment programs nationwide. Additionally, we’ve delivered in-person and web-based provider trainings in the areas of prevention treatment and recovery, substance use disorder and maternal and infant health, effective uses of medication assisted treatment, and improving cultural competence in substance abuse treatment.

“As a company, Bizzell is passionate about developing innovative solutions that lead to positive health outcomes,” says Anton Bizzell, M.D., President and CEO of Bizzell. “We are energized to support SAMSHA’s critical work to advance the nation’s behavioral health—especially now as more people struggle with mental health and substance use concerns and the demand for effective and accessible behavioral health services is growing.”

About Bizzell

About Bizzell Established in 2010, Bizzell is U.S. Small Business Administration (SBA) HUBZone certified strategy, consulting, and technology firm with a mission to improve lives and accelerate change. Bizzell develops innovative solutions to some of the most critical issues of our time such as health care services equity, global health, workforce innovation and other urgent needs facing the world. Under the leadership and vision of founder, Anton C. Bizzell, MD, the company has grown into a thriving firm headquartered in New Carrollton, Maryland with staff and offices in various regions around the country including California, Colorado, and Georgia, and globally in Africa, Asia, and Central America. Learn more about how we develop data-driven, research-informed, innovative solutions to complex-real-world challenges: www.thebizzellgroup.com.

side view of a person's head with a sunset image in it

Supporting Teen Mental Health During a Pandemic

Supporting Teen Mental Health During a Pandemic

Written By: Todd W. Mandell, MD and Rhonda Waller, PhD

The global COVID-19 pandemic is casting new urgency on the topic of teen mental health. Adolescence is already a time of significant physical, mental, emotional, and social development. It is normal for teens to experience a wide range of emotions and unpredictable moods. The COVID-19 pandemic has added a new set of  challenges as teens navigate disruptions to their usual school, extracurricular, and social routines due to lockdowns, social distancing restrictions, and uncertainty about the future. According to a review of relevant research published in June 2020, many teens may experience isolation and loneliness which could lead to or exacerbate feelings of depression and anxiety. Currently, there is little data that examines the impact of pandemics such as COVID-19 on teens’ mental health, though some researchers are starting to explore this topic. Oxford University recently initiated a study that will track adolescents’ mental health to identify factors that hinder and promote resilience during the pandemic. In the meantime, we know that rates of teen depression and anxiety have risen during the past decade.

A 2019 study that examined National Survey on Drug Use and Health (NSDUH) data found that from 2005 to 2017, the percentage of adolescents (12 to 17 years old) experiencing at least one major depressive episode increased from 8.7 percent to 13.01 percent—a 52% increase. In 2018, the rate was 14.4 percent—roughly 3.5 million adolescents. The National Institute of Mental Health reports that nearly one-third (32 percent) of adolescents 13-18 years old experience an anxiety disorder. A 2018 study that examined data from the National Survey of Children’s Health (2003, 2007 and 2011-2012) found that anxiety similarly appears to be on the rise.

While there is no conclusive answer for why teen depression and anxiety are rising, some common themes in research include:

  • Increased awareness about mental health issues might increase disclosure of symptoms and identification of mental health disorders.
  • Continuous exposure to social media and news that may have an adverse impact on teen’s mental health.
  • Increased social and academic pressures and expectations for youth may contribute to depression and anxiety.

In addition, health inequities and social determinants of health such as socioeconomic status, education, social support networks, and access to health care can influence adolescent mental health.

The bottom line, however, is that mental health disorders are a real concern for teens—and the COVID-19 pandemic may exacerbate these issues for some youth. Left untreated, mental health disorders can have a lifelong impact on health. Parents, teachers, coaches, and others who interact with teens should stay alert for signs of anxiety and depression. Warning signs and symptoms may include:

  • Loss of interest in activities previously enjoyed
  • Avoiding school, activities, and social interactions with friends and family
  • Changes in grades
  • Trouble sleeping/concentrating
  • Engaging in self-harming or risky behaviors such as substance abuse
  • Chronic physical complaints
  • Sleeping too much or too little
  • Increased irritability or moodiness

The American Academy of Pediatrics’ parenting website offers  practical information from child health experts on how to support teens’ mental health  during the COVID-19 pandemic, including strategies for healthy routines, effective communication, safe virtual connections, family support, and physical and emotional health. However, parents who observe or are concerned about signs of depression or anxiety in their teen should discuss this with their pediatrician or a health care provider. The U.S. Department of Health and Human Services has also compiled a comprehensive list of Resources to Support Adolescent Mental Health. In addition, the National Institute of Mental Health recommends that teens save several emergency numbers in their cell phones to ensure immediate help for themselves or a friend in an emergency—including the non-emergency local police department number, the Crisis Text Line (741741) and the National Suicide Prevention Lifeline (1-800-273-TALK).

From a public health perspective, increased screening for depression and anxiety and access to health care could result in earlier detection and treatment, which is particularly important during the pandemic. Many experts, including the U.S. Prevention Screening Task Force (USPSTF) and the American Academy of Pediatrics, recommend annual screening of teens for depression. Most insurance companies are now covering telehealth visits at the same rate as in-person visits, which may make screening and services more accessible for teens needing treatment. With growing awareness of the effects of the pandemic on mental health, it is now even more important that teens experiencing depression and anxiety get timely screening and treatment to improve their outcomes.

Todd W. Mandell, MD, Senior Associate, Addiction Medicine. Todd Mandell is a board-certified Psychiatrist with added qualifications in Addiction Medicine, and more than 30 years of experience in the field of co-occurring psychiatric and substance use disorders with a focus on direct patient service, program development, and administration. (LinkedIn)

Rhonda Waller, PhD, Senior Associate, Maternal and Child Health. Rhonda Waller is a psychologist with more than 25 years of professional experience in public health, education, and human services with an emphasis on program development, leadership development, capacity building, and training and technical assistance. (LinkedIn)

The Bizzell Group (Bizzell) was founded by President & CEO Anton C. Bizzell, M.D., a leading behavioral health expert and former Medical Officer for the U.S. Department of Health and Human Services (HHS). Bizzell’s team of public health experts have created and led comprehensive behavioral health prevention and treatment initiatives and education and training programs. Bizzell’s recent work includes systematic, integrated approaches designed to effect lasting change in health and behavioral health care through work with the Substance Abuse and Mental Health Services Administration (SAMHSA), National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), and the Department of Defense (DOD). Learn more about how Bizzell advances data-driven, research-informed, innovative solutions to solve complex-real-world challenges: https://thebizzellgroup.com/

Maintaining Recovery from Substance Use Disorders During the COVID-19 Pandemic

Maintaining Recovery from Substance Use Disorders During the COVID-19 Pandemic

Written by: Anton Bizzell

The global COVID-19 pandemic has had a profound impact on health care delivery systems and on patterns of social support worldwide, creating an unprecedented set of challenges for individuals in recovery from substance use disorders (SUDs). In addition to managing the situational anxiety many people are facing with the unknowns of the pandemic, the social distancing that is vital to reduce the spread of the virus and protect vulnerable people, leaves individuals in recovery physically isolated from their health care providers and support system. Some people with SUDs may be at higher risk of relapsing with extended periods of time at home, uncertainty about work or finances, added stress on family relationships, or social isolation.

With this extraordinary situation, new resources and solutions are emerging to help people struggling with SUDs gain access to treatment in order to maintain their path to recovery.

New treatment access and guidelines during COVID-19. Health care and treatment of individuals with SUDs is evolving to meet the challenges of social isolation during the global pandemic:

  • Telehealth: Most insurance companies are now covering telehealth services at the same rate as traditional in-person visits with health care and behavioral health providers. Providers use secure virtual platforms to conduct a confidential video assessment, and to provide any necessary prescriptions or referrals to additional virtual or in-person treatment.
  • Take-home Medication-Assisted Treatment for Opioid Use Disorders: The Substance Abuse and Mental Health Services Administration (SAMHSA) has issued Opioid Treatment Program guidance for states to be granted an exception to administer 14 to 28 days of take-home medication to individuals in an Opioid Treatment Program. This new guidance improves access to evidence-based Medication-Assisted Treatment for individuals with opioid use disorders (OUDs).
  • Treatment for Alcohol Withdrawal: The American Society of Addiction Medicine (ASAM) has issued a Clinical Guideline on Alcohol Withdrawal Management. Some states have closed liquor stores as part of COVID-19 restrictions, resulting in limited access; at the same time, individuals experiencing alcohol withdrawal may also have limited access to treatment and withdrawal management programs. The ASAM Guideline advises clinicians in decision-making and treatment, improving care for these individuals struggling with alcohol use and alcohol withdrawal.

Virtual support during COVID-19. Many new resources are available to help individuals in recovery access support virtually:

  • SAMHSA Virtual Recovery Resources: SAMHSA notes that during the social distancing and isolation of COVID-19, it is still vital to continue social connections when recovering from SUDs and mental health conditions. This Tip Sheet describes resources for individuals in recovery and gives guidance for setting up a virtual recovery meeting.
  • National Alliance for Mental Illness (NAMI) COVID-19 Resource and Recovery Guide: Mental health support is a vital component of recovery. NAMI provides helpful tips for managing concerns about the virus, accessing virtual support, developing healthy daily routines, maintaining social support, and prioritizing self-care.
  • Alcoholics Anonymous Options for Meeting Online: During COVID-19, many Alcoholics Anonymous groups are exploring alternate ways to continue the community of support for recovery. This may involve phone calls, email, social media, and virtual meetings on digital platforms. Alcoholics Anonymous encourages groups to decide what will work best for them and provides information for groups making this change.
  • Virtual Narcotics Anonymous: This collaborative resource helps people find online and phone meetings of Narcotics Anonymous around the world. Narcotics Anonymous is for people who have any SUD and want support in their recovery.

Healthy habits to support recovery during COVID-19.  Some people in recovery have found it helpful to take this time of social distancing to focus on healthy habits that will support recovery. These can include:

  • Manage News Consumption
    • Check only established, reliable news sources. Set a timer to limit the amount of time you are reading the news. Avoid checking the news within one hour before bedtime, and instead focus on relaxing activities.
  • Get Ample Rest
    • Get at least 7-8 hours of sleep each night. Make sure that your sleeping area is used only for sleep. Use calming routines at night such as reading, taking a bath, or talking with a friend.
  • Develop and Maintain a Daily Routine
    • Keep a routine of getting up and getting dressed on a regular schedule each day. Set your alarm and start your day with a walk outside or your favorite breakfast. Take a shower, get dressed, and write out a plan for how you will spend your day.
  • Exercise Daily
    • Get daily exercise, even if it is just a gentle walk or simple stretches. If you usually go to a gym, look for online exercise programs such as yoga, dance, chair exercises, or even a boot camp routine. Start a virtual exercise routine with a friend so that you can encourage and support each other.
  • Schedule Time to Connect with Loved Ones
    • Schedule time for social connections each day, whether by phone, video, email, or text. Look for shared activities such as a book club, art activities, virtually movie night, or cooking that you can enjoy together remotely. Focus on connections with the people you can have honest conversations with about your feelings and struggles.
  • Other Mental Health Exercises
    • Choose activities that will support your mental health, including breathing exercises, journaling, or meditation. Look for online books and workbooks on Cognitive Behavioral Therapy (CBT), Acceptance and Commitment Therapy (ACT), and Mindfulness, to help you manage your thoughts, worries, and behaviors during this challenging time. Notice what feels relaxing and restful for you, and intentionally choose those activities.

The COVID-19 pandemic has created new challenges for individuals in recovery; it has also fostered creative new approaches to treatment and support, many of which are reaching people in new ways that may continue beyond the end of social distancing. With continued integration of treatment, virtual support, and healthy habits, recovery can continue.

The Bizzell Group (Bizzell) was founded by President & CEO Anton C. Bizzell, M.D., a leading substance use disorders (SUDs) expert and former Medical Officer for the U.S. Department of Health and Human Services (HHS). Dr. Bizzell was selected as Maryland’s 2020 Small Businessperson of the Year by the U.S. Small Business Administration (SBA). Bizzell’s recent work includes systematic, integrated approaches designed to effect lasting change in the field of SUDs through work with the National Institute on Drug Abuse (NIDA), the National Cancer Institute (NCI), the Substance Abuse and Mental Health Services Administration (SAMHSA), the Food and Drug Administration (FDA), the Centers for Disease Control and Prevention (CDC), and the United States Chamber of Commerce Foundation (USCCF). Learn more about how we develop data-driven, research-informed, innovative solutions to SUDs and other complex-real-world challenges: https://BizzellUS.com/

Integrated Strategies to Address Opioid Use Disorders in Women

Integrated Strategies to Address Opioid Use Disorders in Women

By: Anton C. Bizzell, M.D.

The opioid crisis has a complex set of contributing factors in women and requires integrated strategies and solutions. The Center for Behavioral Health Statistics and Quality (CBHSQ) of the Substance Abuse and Mental Health Services Administration (SAMHSA) reports that 19.5 million females (15.4 percent) age 18 years or older used illegal drugs in the past year, and 8.4 million females misused prescription drugs in the past year (CBHSQ, 2017). Opioid use and misuse may have a different progression in women as compared to men, due to differences in sex and gender. The National Institute on Drug Abuse (NIDA) at the National Institutes of Health (NIH) defines differences by sex as pertaining to biological differences, and differences by gender as referring to culturally defined roles for women. Research has shown effects on women who use drugs from hormones, pregnancy, menstrual cycle, and menopause. Women have described reasons for using drugs, such as caregiving, depression and anxiety, fatigue, and coping with pain. Women are also affected by adverse childhood experiences, trauma, post-traumatic stress disorder (PTSD), partner stress, and domestic violence (NIDA, 2019).

In the past, women were not included in research studies at the same rate as men, or the data was not reported separately by sex. The NIH and other federal agencies have made significant efforts to include women, and to research the biological differences in women that are important to understanding how substance use disorders develop and how to treat them effectively.

Researchers know that there are some differences in how substance use disorders develop in women versus men, and continued research will seek to better understand these differences (NIDA, 2019).

  • Dependence: Women sometimes become dependent after using smaller amounts of drugs for a shorter time period, as compared to men.
  • Relapse: In addition to developing dependence more quickly, women may experience more cravings and be more likely to relapse following treatment.
  • Biological factors: Science has also shown differences in brain changes, effects on the heart and blood vessels, and increased sensitivity to drugs due to sex hormones. Women may have a higher likelihood of going to the emergency room or dying from an overdose from some substances, as compared to men.
  • Psychosocial factors: Psychosocial stressors can be a significant factor in opioid misuse and opioid use disorders (OUDs). Women who experience changes in relationships due to divorce or loss of child custody, as well as those who are victims of domestic violence, are at increased risk of developing an OUD. Other stressors such as unemployment, housing instability, caregiving, and untreated mental health conditions can play a role as well.

Substance misuse and OUDs affect millions of women, many of whom are of childbearing age. Most drugs, including opioids, can have serious and harmful effects to a pregnant woman and to an unborn baby. Some substances can increase the risk of miscarriage and stillbirth, in addition to causing health complications to the mother such as high blood pressure and seizures, according to the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) at NIH (2013). Women who are using may be afraid to get help while pregnant, due to fears that they will lose custody of their children, or due to barriers such as stigma, lack of access to treatment programs, or lack of child care. Babies born to women who misuse drugs, especially opioids, can go through withdrawal after birth, a health condition referred to as Neonatal Abstinence Syndrome (NAS). The Office on Women’s Health (OWH) issued Final Report: Opioid Use, Misuse, and Overdose in Women (2017) detailing how the epidemic affects women, and the key prevention, treatment, and recovery issues for women who misuse opioids and who have OUDs. Stakeholders must collaborate to continue to develop relevant research, effective outreach, and evidence-based intervention targeted to the unique needs of women at risk of and affected by opioid use disorders.

Integrated Strategies to Address OUDs Among Women

Integrated strategies are vital to address the complex causes and effects of OUDs in women. The following is list of suggestions for improving health outcomes for women experiencing an OUD:

Research:  More research and data are needed on women who have substance use disorders, and the treatment strategies that are most effective for women.

Education:  Education should focus on prevention, as well as on early identification and treatment of substance use disorders. Partnerships between organizations such as schools, employers, and community centers are essential to reach women of all ages.

Integration of services:  Substance use disorder screening should be integrated into health care, mental health services, and social services. Screen to identify women who are at risk and who need help, and partner with treatment providers to coordinate care across settings.

Whole person care:  Coordinated assessment is needed of all aspects of women’s lives that may be contributing to a substance use disorder and may be a barrier to care. Treat the underlying contributors to substance use disorder and the barriers to recovery, including chronic pain conditions, pressures of caring for elderly parents plus young children, emotional distress and mental health conditions, relationship stress, domestic violence, under- or unemployment, and housing instability. Partner with social services to provide child care while a woman is undergoing treatment, and to address other social stressors in addition to opioid misuse and addiction.

The Bizzell Group’s Experience Addressing OUDs Across the Female Population:

The Bizzell Group (Bizzell) has advanced national and regional efforts over the past decade to improve prevention, identification, and treatment of opioid use disorders in women. The most recent Bizzell projects include:

  • Bizzell partnered with OWH in 2019 to support the meeting Combating Opioid Misuse Among Women and Girls: Prevention Strategies at Work, where 18 grantees and 75 participants discussed projects in 12 states focused on prevention strategies aimed at girls age 10 to 17, women of reproductive age, and older women. Topics included community engagement, pregnant and postpartum women and infants, youth and education, training and capacity building for the clinical workforce, pain management, and health IT and innovation to improve health care delivery.
  • Bizzell partnered with SAMHSA in a multi-year contract to provide technical assistance for approximately 1600 opioid treatment programs nationwide, integrating specific strategies to improve outcomes of women with opioid use disorders.
  • Bizzell partnered with SAMHSA in a multi-year contract to develop and deliver training to over 1500 clinical staff in 16 states through workshops and web-based interactive education, including modules on effective use of medication assisted treatment for pregnant and breastfeeding women.

Are you interested in learning more about Bizzell’s work to improve health outcomes for those affected by the opioid epidemic, including targeted interventions for women and other special populations? At Bizzell, we provide Management Consultation, Technical Assistance, Training, and Subject Matter Expertise in Opioid and other Substance Use Disorders, addressing complex real-world problems with modern, integrated strategies. Visit www.BizzellUS.com or email us: info@BizzellUS.com.

 

References

Center for Behavioral Health Statistics and Quality. (2017). Results from the 2016 National Survey on Drug Use and Health: Detailed Tables. Rockville, MD: Substance Abuse and Mental Health Services Administration. Retrieved from  https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs-2016/NSDUH-DetTabs-2016.pdf.

Eunice Kennedy Shriver National Institute of Child Health and Human Development. (2013). Tobacco, drug use in pregnancy can double risk of stillbirth. Retrieved from  https://www.nichd.nih.gov/news/releases/Pages/121113-stillbirth-drug-use.aspx.

National Institute on Drug Abuse. (2019). Substance Abuse in Women. Retrieved September 19, 2019, from https://www.drugabuse.gov/publications/drugfacts/substance-use-in-women.

Office on Women’s Health. (2017). Final Report: Opioid Use, Misuse, and Overdose in Women. Office on Women’s Health. Retrieved from https://www.womenshealth.gov/files/documents/final-report-opioid-508.pdf.